Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression
April 11, 2022 13:41 ET
|
Clinical Ink
Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today—World Parkinson’s Day—announces research that strengthens its standing as a critical...
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
March 30, 2022 08:30 ET
|
Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
March 17, 2022 09:00 ET
|
JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
March 10, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
January 25, 2022 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
August 19, 2021 18:15 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
October 15, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...